To evaluate the efficacy of peripheral blood biomarkers as prognostic and predictive factors for systemic chemotherapy response and recurrence in breast cancer patients, highlighting their potential impact on clinical decision-making.
Key Findings:
Elevated NLR and PLR are associated with worse disease-free survival (DFS) and overall survival (OS), with p-values indicating statistical significance.
High PDW and MPV levels correlate with poor prognosis in breast cancer patients, supported by statistical analysis.
The study highlights the potential of peripheral blood biomarkers in predicting chemotherapy response and recurrence, suggesting a need for further research.
Interpretation:
The findings suggest that peripheral blood parameters can serve as significant prognostic indicators in breast cancer patients undergoing neoadjuvant chemotherapy, potentially guiding treatment strategies.
Limitations:
The study is retrospective, which may introduce bias in data interpretation.
Sample size and follow-up duration may limit the generalizability of the results, and potential biases in data collection methods should be acknowledged.
Conclusion:
Peripheral blood parameters, particularly inflammatory markers, may provide valuable prognostic information for breast cancer patients undergoing neoadjuvant chemotherapy, emphasizing the need for their integration into clinical practice.
by Tae-in Yoon, Seunghee Baek, Ji hyeon Lee, Tae Kyung Yoo, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sae Byul Lee
